Healthcare (Prescription Drugs)

died · Kansas · House Apr 10, 2026

HB 2551: Enacting the Kansas pharmacy services administrative organization act.

HB 2551 creates a licensing and regulatory framework for pharmacy services administrative organizations (PSAOs) in Kansas. These are entities that help independent pharmacies negotiate contracts with insurance companies and pharmacy benefits managers (PBMs), requiring them to obtain a license from the Kansas Department of Insurance ($200 application fee, $150 annual renewal). The bill mandates PSAOs to disclose ownership details (including ties to drug manufacturers or PBMs) to both the state and pharmacies/PBMs before contracts are signed, prohibits requiring pharmacies to buy specific drugs to access discounts, and requires sharing contract terms and reimbursement rates with pharmacies within 10 days. This directly affects independent pharmacies, PBMs, and PSAOs by increasing transparency and standardizing their business relationships.

Topics ✓ HealthcareSupports HealthcareRegulates PSAOs to improve pharmacy negotiation with insurers, enhancing access to medications and transparency in pharmacy services.85% confidence

Sub-Topics Prescription Drugs

Track

died · Kansas · House Apr 10, 2026

HB 2550: Requiring certain 340B entities to report annually to the Kansas department of insurance on certain costs, savings and payments made under the federal 340B drug pricing program.

HB 2550 requires Kansas hospitals participating in the federal 340B drug pricing program to submit annual reports starting January 1, 2027, to the Kansas Department of Insurance. The reports must detail how hospitals use 340B savings for community services, compare drug acquisition costs under 340B to other pricing sources, and provide specific financial data on drug expenditures, payments to pharmacies, and program administration. The Department of Insurance must publish these reports publicly on its website. This bill applies directly to Kansas hospitals designated as 340B entities under federal law, aiming to increase transparency around how these savings are utilized.

Topics ✓ HealthcareSupports HealthcareMandates reporting on 340B savings usage for community services, ensuring transparency and accountability in program implementation to support healthcare access and proper fund utilization.85% confidence

Sub-Topics Prescription Drugs

Track

died · Kansas · House Apr 10, 2026

HB 2100: Establishing statewide standards governing the use of HIV post-exposure prophylaxis, permitting a pharmacist to initiate such medication to certain patients, providing civil liability protections to pharmacists who initiate prophylactic therapy to patients for post-exposure to human immunodeficiency virus.

HB 2100 allows pharmacists in Kansas to initiate HIV post-exposure prophylaxis (PEP) medication for patients who believe they've been exposed to HIV, directly affecting pharmacists and those at risk of HIV exposure. The bill requires the state board of pharmacy to create a statewide protocol mandating proper patient education on PEP use, safe administration, and follow-up care with a doctor, alongside accurate recordkeeping. Pharmacists acting in good faith under this protocol are protected from civil lawsuits, criminal charges, or professional discipline related to initiating PEP. The protocol must be established by January 1, 2026, to ensure timely access to HIV prevention medication outside of traditional medical settings.

Topics ✓ HealthcareSupports HealthcareExpands patient access to HIV PEP by allowing pharmacists to initiate treatment under state protocols, improving timely care for at-risk individuals without requiring immediate physician consultation.95% confidence

Sub-Topics Prescription Drugs

Track

died · Kansas · House Apr 10, 2026

HB 2364: Prohibiting certain health insurers from requiring cost-sharing for nonopioid prescription drugs or providing less favorable coverage for such drug than that for opioid or narcotic prescription drugs for the treatment of pain.

HB 2364 requires health insurers (including Medicaid, CHIP, and state employee plans) to provide equal coverage for FDA-approved nonopioid pain medications as for opioid or narcotic drugs. Specifically, insurers cannot deny coverage for nonopioid drugs in favor of opioids, force patients to try opioids first, or impose higher out-of-pocket costs (like copays or stricter prior authorization) on nonopioid drugs compared to opioids. The bill ensures nonopioid pain medications are not disadvantaged in formulary tiers or coverage rules. It directly affects patients prescribed nonopioid pain treatments and insurers managing drug coverage. The law takes effect upon publication in the statute book.

Topics ✓ HealthcareSupports HealthcareRequires equal coverage for nonopioid pain medications vs opioids, preventing higher costs or barriers, expanding patient access to alternative pain treatments.95% confidence

Sub-Topics Children's Health Prescription Drugs Substance Abuse

Track

died · Kansas · House Apr 10, 2026

HB 2244: Modifying the composition of the board of pharmacy and prohibiting the board of pharmacy from adopting rules and regulations that would limit or condition the use of telepharmacy.

HB 2244 modifies Kansas' pharmacy board composition and prohibits the board from restricting telepharmacy use. It requires the board to include three pharmacist types (community, chain pharmacy, specialty/mail-order) plus a public member, and explicitly bans rules limiting telepharmacy based on population, distance from physical pharmacies, or network adequacy. The bill defines telepharmacy as remote pharmacist services using technology for real-time patient care and counseling at registered locations. These changes directly affect pharmacists, telepharmacy providers, and patients seeking remote pharmacy services across Kansas.

Topics ✓ HealthcareSupports HealthcareProhibits restrictions on telepharmacy, expanding patient access to remote pharmacist services and counseling per bill's explicit language.95% confidence ✓ TechnologySupports TechnologyProhibits restrictions on telepharmacy technology, enabling remote pharmacist services via digital means, directly advancing tech use in healthcare access.95% confidence

Sub-Topics Prescription Drugs

Track

died · Kansas · House Apr 10, 2026

HB 2369: Allowing pharmacists to administer certain vaccines to children and adults pursuant to a vaccination protocol.

HB 2369 allows Kansas pharmacists to administer certain vaccines to patients aged seven or older (or as recommended by the CDC) under a vaccination protocol. This applies to vaccines approved by the U.S. Food and Drug Administration (FDA), excluding specific vaccines like cholera, rabies, smallpox, and any vaccine approved after January 1, 2023. The bill expands pharmacists' scope of practice for routine vaccinations without requiring physician orders for eligible vaccines. It replaces the previous pharmacy act provision with these updated rules, effective upon publication.

Topics ✓ HealthcareSupports HealthcareExpands pharmacist scope to administer vaccines without physician orders, improving patient access to routine vaccinations under CDC/FDA guidelines.90% confidence

Sub-Topics Healthcare Workforce Medical Licensing Prescription Drugs

Track

died · Kansas · Senate Apr 10, 2026

SB 212: Enacting the prescription drug cost and affordability review act to establish the prescription drug pricing board and prescription drug affordability stakeholder council to review the cost of prescription medications and establish upper payment limits for certain prescription drugs.

SB 212 establishes a Prescription Drug Affordability Board within Kansas' Insurance Department and a Prescription Drug Affordability Stakeholder Council. The Board will review prescription drug costs and set upper payment limits for certain brand name, generic, biologic, and biosimilar drugs using the Consumer Price Index as a benchmark. The Council, with 21 members representing manufacturers, pharmacies, insurers, employers, and the public, will advise the Board on pricing. This bill directly affects drug manufacturers, health insurers, pharmacies, and patients by creating a formal process to cap prices for specific prescription medications.

Topics ✓ Budget & TaxesSupports Budget & TaxesSets upper drug payment limits, reducing state healthcare spending and promoting fiscal responsibility through cost control.85% confidence ✓ HealthcareSupports HealthcareEstablishes board to cap drug prices, directly improving affordability and patient access to medications per bill's explicit purpose.95% confidence

Sub-Topics Prescription Drugs

Track

died · Kansas · House Apr 10, 2026

HB 2081: Substitute for HB 2081 by Committee on Taxation - Providing a sales tax exemption for community pharmacies serving medically underserved individuals and families.

This bill would exempt community pharmacies serving medically underserved areas from paying sales tax on their business purchases. It directly affects local pharmacies in communities with limited healthcare access, including those providing services to low-income or rural residents. The key provision removes sales tax for pharmacy purchases used to serve medically underserved patients, reducing operating costs for these providers. This policy change applies specifically to pharmacies meeting the "medically underserved" criteria defined in the bill. The exemption modifies Kansas' existing tax code to include these pharmacies under the sales tax exemption list.

Topics ✓ Budget & TaxesSupports Budget & TaxesExempts community pharmacies from sales tax on business purchases, reducing costs for providers serving medically underserved low-income/rural communities.95% confidence ✓ HealthcareSupports HealthcareExempts community pharmacies in underserved areas from sales tax, reducing operating costs to improve healthcare access for low-income/rural residents.92% confidence

Sub-Topics Sales Tax Tax Incentives Prescription Drugs

Track

died · Kansas · Senate Apr 10, 2026

SB 284: Enacting the defense of drug delivery act to prohibit manufacturer interference relating to 340B drug distribution.

SB 284, the "Defense of Drug Delivery Act," prohibits drug manufacturers from restricting how 340B drugs are distributed to covered healthcare entities (like hospitals and clinics participating in the federal 340B drug pricing program). It specifically bans manufacturers from denying, limiting, or discriminating against the delivery of 340B drugs to these entities unless prohibited by federal law or state law. The bill also prevents manufacturers from requiring covered entities to share health information, claims data, or purchasing details unless voluntarily provided or legally mandated. This directly affects covered entities by ensuring they can access discounted drugs without manufacturer-imposed barriers.

Topics ✓ HealthcareSupports HealthcarePrevents drug manufacturers from restricting 340B drug distribution, ensuring covered healthcare entities maintain access to discounted medications under federal program.95% confidence

Sub-Topics Prescription Drugs

Track